局部治疗在癌基因成瘾的非小细胞肺癌寡进展性疾病中的作用
该回顾性研究纳入89例携带EGFR/BRAF V600E突变或ALK/ROS1/RET重排的转移性非小细胞肺癌患者,这些患者在酪氨酸激酶抑制剂治疗期间出现≤5个部位的寡进展并接受局部放疗;中位PFS1为10.2个月(95%CI 8.7-13.1),中位Extended-PFS为6.7个月(95%CI 4.9-8.3),不同驱动基因间Extended-PFS相似;结论认为局部放疗可有效延长靶向治疗持续时间。
要点
- 75.4%的局部放疗疗程针对单个病灶。
- 中位PFS1为10.2个月(95%CI 8.7-13.1),中位Extended-PFS为6.7个月(95%CI 4.9-8.3)。
- 接受单部位局部放疗的患者中51.4%在下一次疾病进展时仍仅有1个部位。
核心结论
- 局部放疗可有效延长多种癌基因成瘾的非小细胞肺癌患者在酪氨酸激酶抑制剂上的治疗持续时间。
研究设计与样本
- 回顾性分析纳入89例携带EGFR/BRAF V600E突变或ALK/ROS1/RET重排的转移性非小细胞肺癌患者,这些患者在相应酪氨酸激酶抑制剂治疗期间出现寡进展(≤5个部位)并接受局部放疗。
- PFS1定义为含酪氨酸激酶抑制剂方案开始至首次因寡进展接受局部放疗的时间;后续PFS(如PFS2、PFS3)定义为前次局部放疗至后续局部放疗、更换全身治疗、死亡或失访(以先发生者为准)的时间;Extended-PFS定义为首次局部放疗第一天至更换全身治疗、死亡或失访(以先发生者为准)的时间。
主要发现
- 75.4%的局部放疗疗程针对单个病灶。
- 中位PFS1为10.2个月(95%CI 8.7-13.1)。
- 中位Extended-PFS为6.7个月(95%CI 4.9-8.3)。
- Extended-PFS在不同致癌驱动基因间相似。
- 接受单部位局部放疗的患者中51.4%在下一次疾病进展时仅有1个部位。
临床怎么用
- 原文未据此给出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We first described the role of local radiation therapy (LT) for oligoprogressive disease (OPD) on targeted therapy in 2012. Here, we present an updated and larger data set and extend the analysis beyond EGFR and ALK. METHODS: A retrospective review of patients with metastatic NSCLC harboring EGFR/BRAF V600E mutations, or ALK/ROS1/RET rearrangements, who had OPD on respective tyrosine-kinase inhibitor (TKI) and treated with LT was performed. OPD was defined as disease progression on therapy in ≤5 sites. PFS1 (progression-free survival 1) was defined as time from initiation of TKI-containing regimen to the first course of LT for OPD. Subsequent PFS times (eg, PFS2, PFS3) were defined as time from prior LT to subsequent LT, switch of systemic therapy, death, or loss to follow-up, whichever occurred first. Extended-PFS was defined as time from the first day of the first LT course to the day of change in systemic therapy, death, or loss to follow-up, whichever came first. RESULTS: Eighty-nine patients were identified. In 75.4% of the LT courses, a single lesion was treated. Median PFS1 was 10.2 months (95% CI, 8.7-13.1) and median Extended-PFS was 6.7 months (95% CI, 4.9-8.3). Extended-PFS was similar across different oncogenic drivers; 51.4% of patients who underwent LT to a single site had only 1 site on next disease progression. CONCLUSIONS: LT is effective in prolonging treatment duration on TKI in oncogene-addicted NSCLC across multiple oncogenes.
引用
- Tsui DCC, Holt DE, Patil T, et al. The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer. Adv Radiat Oncol. 2024. PMID: 38868503. doi:10.1016/j.adro.2024.101516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。